Developer docs
API playgroundTry for free, no card

Search company profiles

Polpharma Biologics

Full company profile

uuid00061sb

Namestring
Polpharma Biologics
Legal namestring
Polpharma Biologics S.A.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Polpharma Biologics is a European biopharmaceutical company that develops, manufactures, and out-licenses biosimilar medicines. Founded as the biotech division of Polpharma in 2010 and spun off as an independent entity in 2019, the company underwent a structural transformation in September 2025, with its biosimilars business relocating to Zug, Switzerland, while its CDMO operations spun out as Rezon Bio in Poland. The company maintains integrated capabilities spanning cell line development (Utrecht, Netherlands), R&D and drug substance manufacturing (Gdańsk, Poland), and commercial-scale manufacturing with twin 2000L bioreactor capacity (Warsaw-Duchnice, Poland). It employs approximately 900 specialists across these operations, with over 10% holding doctoral degrees.

Polpharma Biologics operates a pure B2B out-licensing model with no direct commercialization. It develops biosimilars through clinical and regulatory stages, then partners with global pharmaceutical companies that handle commercialization, marketing, and distribution in licensed territories. Commercial partners include Sandoz (global for natalizumab), Teva (Europe/Canada for ranibizumab), Fresenius Kabi (global ex-MENA for vedolizumab), and others. Revenue flows from upfront payments, development milestones, supply agreements, and commercial royalties. The company holds a 50% stake in the Bioeq AG joint venture with Formycon AG for ranibizumab commercialization.

The product portfolio includes two FDA/EMA-approved biosimilars, Tyruko (natalizumab, the first and only FDA-approved MS biosimilar, launched in the US in November 2025) and Ranivisio/NUFYMCO (ranibizumab for ophthalmology, available in 22 countries), plus a pipeline of three biosimilars in development: PB016 (vedolizumab), PB018 (ocrelizumab), and PB019 (guselkumab). The company is privately controlled by Polish entrepreneur Jerzy Starak and is not publicly traded.

Short descriptiontext

Polpharma Biologics is a Switzerland-based biopharmaceutical company that develops, manufactures, and out-licenses biosimilar medicines to global pharmaceutical partners, with two FDA/EMA-approved products (natalizumab and ranibizumab) and a pipeline targeting neurology, ophthalmology, gastroenterology, and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar development, biologics manufacturing, monoclonal antibody biosimilars, cell line development, pharmaceutical out-licensing
Industry3 codes
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilar Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biosimilar Out-licensing
TypeLicensing Royalties
Description

Polpharma Biologics develops biosimilars through clinical stages and out-licenses commercialization rights to pharmaceutical partners. The company retains responsibility for development, manufacturing, and supply while partners handle commercialization, marketing, and distribution. Revenue flows from upfront payments, development milestones, and commercial royalties based on partner sales.

polpharmabiologics.com
2CDMO Services
TypeProfessional Services
Description

Through its former CDMO operations (now operating as Rezon Bio), Polpharma Biologics provides contract development and manufacturing services for biologics to external biotech and pharmaceutical companies. Services include cell line development, process development, clinical and commercial manufacturing, and fill-finish capabilities.

polpharmabiologics.com
3Joint Venture (Bioeq)
TypeLicensing Royalties
Description

Polpharma Biologics holds 50% stake in Bioeq AG, a joint venture with Formycon AG for development and commercialization of biosimilars including ranibizumab. Revenue shared from commercialization agreements with partners like Teva, Coherus, and Zydus.

polpharmabiologics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Tyruko
Description

Natalizumab biosimilar brand for multiple sclerosis, commercialized by Sandoz in the US

polpharmabiologics.com
+5 more records
Core offering1 text field

Polpharma Biologics develops and manufactures biosimilar medicines through integrated capabilities spanning cell line development, process development, clinical manufacturing, and commercial-scale production using mammalian and microbial expression systems. The company out-licenses its biosimilars (natalizumab Tyruko®, ranibizumab Ranivisio®/NUFYMCO®, plus pipeline candidates PB016, PB018, PB019) to global pharmaceutical partners who commercialize, market, and distribute them in licensed territories worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First and only FDA-approved biosimilar for natalizumab for multiple sclerosis treatment
+3 more records
Product overview1 text field

Polpharma Biologics is a biopharmaceutical group that develops and manufactures biosimilar medicines. Following a 2025 demerger, the company operates its biosimilars business under the Polpharma Biologics brand from Switzerland, while its CDMO services are now provided by Rezon Bio from Poland. The commercialized biosimilar portfolio includes Tyruko® (natalizumab) for multiple sclerosis and Crohn's disease, Ranivisio®/NUFYMCO® (ranibizumab) for ophthalmology indications, with additional pipeline candidates PB016 (vedolizumab), PB018 (ocrelizumab), and PB019 (guselkumab) in development. The company leverages contract development and manufacturing partners to deliver end-to-end biosimilars from cell line development to finished products across major therapeutic areas including neurology, immunology, gastroenterology, and ophthalmology.

Product and service7 records
1Tyruko® (natalizumab-sztn)
CategoryBiosimilar Product - Neurology/Immunology
Description

First and only FDA-approved biosimilar of natalizumab for treatment of relapsing forms of multiple sclerosis (MS) and adult patients with moderately to severely active Crohn's disease. Commercialized by Sandoz under exclusive global license; available in U.S. and 14 European countries.

2Ranivisio® (ranibizumab)
CategoryBiosimilar Product - Ophthalmology
Description

Biosimilar to Lucentis® (ranibizumab) approved for treatment of debilitating retinopathies including neovascular age-related macular degeneration (AMD), diabetic macular edema, proliferative diabetic retinopathy, and macular edema following retinal vein occlusion. Available in EU, US, UK, Canada, Brazil and 22 countries worldwide under different tradenames including Ranivisio, ONGAVIA, CIMERLI, and RANOPTO.

3Ranivisio® PFS (ranibizumab pre-filled syringe)
CategoryBiosimilar Product - Ophthalmology
Description

First Lucentis® biosimilar offered in pre-filled syringe presentation in Europe. Used for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Pre-filled syringe presentation enables precise dosing and ease of use for ophthalmic treatments.

4NUFYMCO® (interchangeable ranibizumab biosimilar)
CategoryBiosimilar Product - Ophthalmology
Description

Interchangeable biosimilar to Lucentis® (ranibizumab) with BLA approved by USFDA. Commercialized by Zydus Lifesciences in the United States under licensing, supply and commercialization agreement.

5PB016 (vedolizumab biosimilar)
CategoryBiosimilar Product - Gastroenterology/IBD (Pipeline)
Description

Proposed biosimilar to Entyvio® (vedolizumab), an integrin receptor antagonist for moderate to severe ulcerative colitis and Crohn's disease. Licensed globally (excluding MENA) to Fresenius Kabi for commercialization; Polpharma Biologics leads development and manufacturing. Phase 1 PK/PD comparability demonstrated.

6PB018 (ocrelizumab biosimilar)
CategoryBiosimilar Product - Neurology/Immunology (Pipeline)
Description

Proposed biosimilar to Ocrevus® (ocrelizumab), an anti-CD20 monoclonal antibody therapy for treatment of relapsing and primary progressive forms of Multiple Sclerosis. In Phase 1 clinical development; licensed to MS Pharma for the MENA region.

7PB019 (guselkumab biosimilar)
CategoryBiosimilar Product - Dermatology/Immunology (Pipeline)
Description

Proposed biosimilar to guselkumab (Tremfya®), a monoclonal antibody targeting IL-23 for treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Licensed to MS Pharma for MENA region commercialization.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-03
Description

Collaboration for execution of Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus (ocrelizumab), in patients with Multiple Sclerosis. Randomized, double-blind, parallel-group study to compare PK, PD, safety, and immunogenicity. Study expected to begin October 2026 with approximately 222 participants.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-22
Description

Licensing agreement for autoimmune disease biosimilar across Latin America excluding Brazil. Tuteur obtains exclusive rights to commercialize; Polpharma retains full responsibility for development and manufacturing. Regulatory submission anticipated within three years.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-23
Description

Licensing, supply, and commercialization agreement for NUFYMCO (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis, in the United States. Bioeq oversees development, manufacturing, registration and supply; Zydus responsible for commercialization. BLA approved by FDA.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-10
Description

Licensing agreement for autoimmune disease biosimilar commercialization in Brazil. Libbs gains exclusive rights to commercialize; Polpharma retains full responsibility for development and manufacturing. Regulatory submission expected within three years.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-02
Description

Licensing agreements for commercialization of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) biosimilars in MENA region. MS Pharma responsible for registration, marketing, and distribution. Fill and finish activities to be transferred to MS Pharma's biologics manufacturing facility in Saudi Arabia.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-05
Description

Global (except Middle East & North Africa) licensing agreement for commercialization of PB016, a proposed biosimilar to vedolizumab (Entyvio) for ulcerative colitis and Crohn's disease. Polpharma leads development and manufacturing; Fresenius Kabi holds exclusive commercialization rights worldwide excluding MENA.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-04
Description

Brazil exclusive commercialization partner for Ranivisio (ranibizumab biosimilar) for treatment of debilitating retinopathies approved by ANVISA. Polpharma Biologics manufactures drug substance and passed ANVISA inspection receiving Brazilian GMP certificate.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Strategic partnership for end-to-end development and manufacture of a biosimilar product for the global market. Chime provides integrated support from IND stage through commercial supply. Specific therapy and indication not disclosed.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-08-25
Description

Academic, scientific and technological cooperation agreement. Joint activities include training of biotechnology specialists and joint research projects. Part of building international scientific cooperation platform.

10Sandoz AG
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-09-03
Description

Global commercialization agreement for natalizumab biosimilar. Polpharma Biologics responsible for development, manufacturing and supply. Sandoz commercializes and distributes upon approval under exclusive global license. The biosimilar (Tyruko) received FDA approval and launched in US in November 2025, and is available in 14 European countries.

polpharmabiologics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture between Polpharma Biologics Group and Formycon AG for development, licensing, and commercialization of biosimilars including ranibizumab (Ranivisio/NUFYMCO). Polpharma holds 50% stake. Bioeq coordinates development while partners manufacture drug substance (Polpharma) and commercialize globally (Teva, Coherus, Zydus, MS Pharma, Biomm).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Coherus is a US-based biosimilar-focused biopharma (Cimerli ranibizumab, Yusimry adalimumab, Udenyca pegfilgrastim) and is also a Polpharma commercialization partner for Ranivisio in the US. As a pure-play biosimilar company, it is a tight peer with comparable economics and target markets.

TypeDirect peer
Description

Celltrion is one of the world's leading biosimilar developers (Remsima/Inflectra, Truxima, Herzuma, Yukarcin, Vegzelma). It is a direct competitor in mAb biosimilars across oncology and immunology, and like Polpharma pursues global out-licensing and direct commercialization in select geographies.

TypeBroad incumbent
Description

Amgen operates a biosimilar business unit (Amgevita, Kanjinti, Mvasi, Soliris biosimilars) as part of a much broader biopharma portfolio. It is a relevant comparable given Polpharma's mAb biosimilar focus, though Amgen is also a competitor (e.g., Amgevita vs. adalimumab biosimilars) and a peer biologics developer.

TypeDirect peer
Description

Samsung Bioepis is a major biosimilar developer commercializing multiple biosimilars (etanercept, adalimumab, trastuzumab, ranibizumab/SB11, bevacizumab). It directly competes with Polpharma's Ranivisio in the ranibizumab biosimilar market and pursues an out-licensing model with Biogen/Samsung.

TypeDirect peer
Description

Biocon Biologics is a leading biosimilar developer (trastuzumab, bevacizumab, adalimumab, pegfilgrastim, insulin glargine) with integrated manufacturing. Like Polpharma, it uses out-licensing partners (Viatris) for global reach and is pursuing its own pipeline in autoimmune and oncology biosimilars.

TypeDirect peer
Description

Zydus Lifesciences (Cadila) is a vertically integrated Indian biosimilar and generics developer that commercializes its own products in the US, India, and emerging markets. It is a Polpharma commercialization partner for NUFYMCO in the US and pursues a directly comparable biosimilar portfolio across immunology, oncology, and ophthalmology.

TypeDirect peer
Description

Alvotech is a vertically integrated biosimilar developer and manufacturer with a comparable focus on monoclonal antibody biosimilars (ranibizumab, adalimumab, ustekinumab, denosumab). Like Polpharma, it operates a hub-and-spoke model with manufacturing in Iceland/India and global commercialization partners, and competes directly in the ophthalmology biosimilar space with Polpharma's Ranivisio.

TypeDirect peer
Description

Formycon is Polpharma's Bioeq AG joint venture partner and an independent biosimilar developer (FYB201 ranibizumab, FYB202/203 ustekinumab, FYB206 Keytruda biosimilar). It is a direct comparable in biosimilar pipeline strategy and has the same IP/commercialization partner model.

9Sandoz
TypeBroad incumbent
Description

Sandoz (recently spun off from Novartis) is the world's largest generic and biosimilar medicines company, developing and commercializing biosimilars (Hyrimoz, Omnitrope, Erelzi, Zessly, Tyruko). It is both Polpharma's largest commercial partner (Tyruko global rights) and a competitor in the biosimilar space.

TypeBroad incumbent
Description

Teva is the world's largest generic drug manufacturer with a biosimilars business, including Tbo-filgrastim and partnerships (Polpharma's Ranivisio in EU/Canada). It is both a direct competitor in biosimilars and a Polpharma commercialization partner, making it a relevant broad-incumbent peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polpharma Biologics

Biosimilar Pharmaceuticalspolpharmabiologics.com

Polpharma Biologics is a Switzerland-based biopharmaceutical company that develops, manufactures, and out-licenses biosimilar medicines to global pharmaceutical partners, with two FDA/EMA-approved products (natalizumab and ranibizumab) and a pipeline targeting neurology, ophthalmology, gastroenterology, and autoimmune diseases.

What Polpharma Biologics does

Polpharma Biologics is a European biopharmaceutical company that develops, manufactures, and out-licenses biosimilar medicines. Founded as the biotech division of Polpharma in 2010 and spun off as an independent entity in 2019, the company underwent a structural transformation in September 2025, with its biosimilars business relocating to Zug, Switzerland, while its CDMO operations spun out as Rezon Bio in Poland. The company maintains integrated capabilities spanning cell line development (Utrecht, Netherlands), R&D and drug substance manufacturing (Gdańsk, Poland), and commercial-scale manufacturing with twin 2000L bioreactor capacity (Warsaw-Duchnice, Poland). It employs approximately 900 specialists across these operations, with over 10% holding doctoral degrees.

Polpharma Biologics operates a pure B2B out-licensing model with no direct commercialization. It develops biosimilars through clinical and regulatory stages, then partners with global pharmaceutical companies that handle commercialization, marketing, and distribution in licensed territories. Commercial partners include Sandoz (global for natalizumab), Teva (Europe/Canada for ranibizumab), Fresenius Kabi (global ex-MENA for vedolizumab), and others. Revenue flows from upfront payments, development milestones, supply agreements, and commercial royalties. The company holds a 50% stake in the Bioeq AG joint venture with Formycon AG for ranibizumab commercialization.

The product portfolio includes two FDA/EMA-approved biosimilars, Tyruko (natalizumab, the first and only FDA-approved MS biosimilar, launched in the US in November 2025) and Ranivisio/NUFYMCO (ranibizumab for ophthalmology, available in 22 countries), plus a pipeline of three biosimilars in development: PB016 (vedolizumab), PB018 (ocrelizumab), and PB019 (guselkumab). The company is privately controlled by Polish entrepreneur Jerzy Starak and is not publicly traded.

Polpharma Biologics firmographics

Firmographics
Name
Polpharma Biologics
Legal name
Polpharma Biologics S.A.
Website
https://polpharmabiologics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
251–500 employees
Short description
Polpharma Biologics is a Switzerland-based biopharmaceutical company that develops, manufactures, and out-licenses biosimilar medicines to global pharmaceutical partners, with two FDA/EMA-approved products (natalizumab and ranibizumab) and a pipeline targeting neurology, ophthalmology, gastroenterology, and autoimmune diseases.
Ownership category
akta.pro rank

Polpharma Biologics industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Biosimilar development
  • Biologics manufacturing
  • Monoclonal antibody biosimilars
  • Cell line development
  • Pharmaceutical out-licensing

Where Polpharma Biologics is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices6 records

Markets served

Polpharma Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

  1. Biosimilar Out-licensing: Polpharma Biologics develops biosimilars through clinical stages and out-licenses commercialization rights to pharmaceutical partners. The company retains responsibility for development, manufacturing, and supply while partners handle commercialization, marketing, and distribution. Revenue flows from upfront payments, development milestones, and commercial royalties based on partner sales.
  2. CDMO Services: Through its former CDMO operations (now operating as Rezon Bio), Polpharma Biologics provides contract development and manufacturing services for biologics to external biotech and pharmaceutical companies. Services include cell line development, process development, clinical and commercial manufacturing, and fill-finish capabilities.
  3. Joint Venture (Bioeq): Polpharma Biologics holds 50% stake in Bioeq AG, a joint venture with Formycon AG for development and commercialization of biosimilars including ranibizumab. Revenue shared from commercialization agreements with partners like Teva, Coherus, and Zydus.

Go-to-market motion3 records

Distribution channels8 records

Marketing channels7 records

Polpharma Biologics product offering

Product offering

Core offering

Polpharma Biologics develops and manufactures biosimilar medicines through integrated capabilities spanning cell line development, process development, clinical manufacturing, and commercial-scale production using mammalian and microbial expression systems. The company out-licenses its biosimilars (natalizumab Tyruko®, ranibizumab Ranivisio®/NUFYMCO®, plus pipeline candidates PB016, PB018, PB019) to global pharmaceutical partners who commercialize, market, and distribute them in licensed territories worldwide.

Product overview

Polpharma Biologics is a biopharmaceutical group that develops and manufactures biosimilar medicines. Following a 2025 demerger, the company operates its biosimilars business under the Polpharma Biologics brand from Switzerland, while its CDMO services are now provided by Rezon Bio from Poland. The commercialized biosimilar portfolio includes Tyruko® (natalizumab) for multiple sclerosis and Crohn's disease, Ranivisio®/NUFYMCO® (ranibizumab) for ophthalmology indications, with additional pipeline candidates PB016 (vedolizumab), PB018 (ocrelizumab), and PB019 (guselkumab) in development. The company leverages contract development and manufacturing partners to deliver end-to-end biosimilars from cell line development to finished products across major therapeutic areas including neurology, immunology, gastroenterology, and ophthalmology.

Differentiator

Problem solved

Functional benefit

Brands

  • Tyruko: Natalizumab biosimilar brand for multiple sclerosis, commercialized by Sandoz in the US
  • Ranivisio
  • ONGAVIA
  • CIMERLI
  • RANOPTO
  • NUFYMCO

Products and services

  • Tyruko® (natalizumab-sztn) First and only FDA-approved biosimilar of natalizumab for treatment of relapsing forms of multiple sclerosis (MS) and adult patients with moderately to severely active Crohn's disease. Commercialized by Sandoz under exclusive global license; available in U.S. and 14 European countries.
  • Ranivisio® (ranibizumab) Biosimilar to Lucentis® (ranibizumab) approved for treatment of debilitating retinopathies including neovascular age-related macular degeneration (AMD), diabetic macular edema, proliferative diabetic retinopathy, and macular edema following retinal vein occlusion. Available in EU, US, UK, Canada, Brazil and 22 countries worldwide under different tradenames including Ranivisio, ONGAVIA, CIMERLI, and RANOPTO.
  • Ranivisio® PFS (ranibizumab pre-filled syringe) First Lucentis® biosimilar offered in pre-filled syringe presentation in Europe. Used for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Pre-filled syringe presentation enables precise dosing and ease of use for ophthalmic treatments.
  • NUFYMCO® (interchangeable ranibizumab biosimilar) Interchangeable biosimilar to Lucentis® (ranibizumab) with BLA approved by USFDA. Commercialized by Zydus Lifesciences in the United States under licensing, supply and commercialization agreement.
  • PB016 (vedolizumab biosimilar) Proposed biosimilar to Entyvio® (vedolizumab), an integrin receptor antagonist for moderate to severe ulcerative colitis and Crohn's disease. Licensed globally (excluding MENA) to Fresenius Kabi for commercialization; Polpharma Biologics leads development and manufacturing. Phase 1 PK/PD comparability demonstrated.
  • PB018 (ocrelizumab biosimilar) Proposed biosimilar to Ocrevus® (ocrelizumab), an anti-CD20 monoclonal antibody therapy for treatment of relapsing and primary progressive forms of Multiple Sclerosis. In Phase 1 clinical development; licensed to MS Pharma for the MENA region.
  • PB019 (guselkumab biosimilar) Proposed biosimilar to guselkumab (Tremfya®), a monoclonal antibody targeting IL-23 for treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Licensed to MS Pharma for MENA region commercialization.

Quantifiable outcome

  • First and only FDA-approved biosimilar for natalizumab for multiple sclerosis treatment
  • +3 more outcomes

Companies that use Polpharma Biologics

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles1 record

Polpharma Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Polpharma Biologics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered supporting, major, core and strategic.

  • PSI CROsupportingImplementation/ SI/ Consulting Partner · 3 June 2026Collaboration for execution of Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus (ocrelizumab), in patients with Multiple Sclerosis. Randomized, double-blind, parallel-group study to compare PK, PD, safety, and immunogenicity. Study expected to begin October 2026 with approximately 222 participants.
  • TuteurmajorChannel Partner/ Reseller/ Distributor · 22 May 2026Licensing agreement for autoimmune disease biosimilar across Latin America excluding Brazil. Tuteur obtains exclusive rights to commercialize; Polpharma retains full responsibility for development and manufacturing. Regulatory submission anticipated within three years.
  • Zydus LifesciencesmajorChannel Partner/ Reseller/ Distributor · 23 December 2025Licensing, supply, and commercialization agreement for NUFYMCO (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis, in the United States. Bioeq oversees development, manufacturing, registration and supply; Zydus responsible for commercialization. BLA approved by FDA.
  • Libbs FarmacêuticamajorChannel Partner/ Reseller/ Distributor · 10 December 2025Licensing agreement for autoimmune disease biosimilar commercialization in Brazil. Libbs gains exclusive rights to commercialize; Polpharma retains full responsibility for development and manufacturing. Regulatory submission expected within three years.
  • MS PharmacoreChannel Partner/ Reseller/ Distributor · 2 September 2025Licensing agreements for commercialization of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) biosimilars in MENA region. MS Pharma responsible for registration, marketing, and distribution. Fill and finish activities to be transferred to MS Pharma's biologics manufacturing facility in Saudi Arabia.
  • Fresenius KabicoreChannel Partner/ Reseller/ Distributor · 5 August 2025Global (except Middle East & North Africa) licensing agreement for commercialization of PB016, a proposed biosimilar to vedolizumab (Entyvio) for ulcerative colitis and Crohn's disease. Polpharma leads development and manufacturing; Fresenius Kabi holds exclusive commercialization rights worldwide excluding MENA.
  • Biomm SAmajorChannel Partner/ Reseller/ Distributor · 4 June 2025Brazil exclusive commercialization partner for Ranivisio (ranibizumab biosimilar) for treatment of debilitating retinopathies approved by ANVISA. Polpharma Biologics manufactures drug substance and passed ANVISA inspection receiving Brazilian GMP certificate.
  • Chime BiologicsstrategicStrategic or Co-development Partner · 16 April 2025Strategic partnership for end-to-end development and manufacture of a biosimilar product for the global market. Chime provides integrated support from IND stage through commercial supply. Specific therapy and indication not disclosed.
  • University of WarsawsupportingStrategic or Co-development Partner · 25 August 2020Academic, scientific and technological cooperation agreement. Joint activities include training of biotechnology specialists and joint research projects. Part of building international scientific cooperation platform.
  • Sandoz AGcoreChannel Partner/ Reseller/ Distributor · 3 September 2019Global commercialization agreement for natalizumab biosimilar. Polpharma Biologics responsible for development, manufacturing and supply. Sandoz commercializes and distributes upon approval under exclusive global license. The biosimilar (Tyruko) received FDA approval and launched in US in November 2025, and is available in 14 European countries.
  • Bioeq AGcoreStrategic or Co-development PartnerJoint venture between Polpharma Biologics Group and Formycon AG for development, licensing, and commercialization of biosimilars including ranibizumab (Ranivisio/NUFYMCO). Polpharma holds 50% stake. Bioeq coordinates development while partners manufacture drug substance (Polpharma) and commercialize globally (Teva, Coherus, Zydus, MS Pharma, Biomm).

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Polpharma Biologics competitors and assessment

Company assessment

Direct peers

  • Coherus BioSciences: Coherus is a US-based biosimilar-focused biopharma (Cimerli ranibizumab, Yusimry adalimumab, Udenyca pegfilgrastim) and is also a Polpharma commercialization partner for Ranivisio in the US. As a pure-play biosimilar company, it is a tight peer with comparable economics and target markets.
  • Celltrion: Celltrion is one of the world's leading biosimilar developers (Remsima/Inflectra, Truxima, Herzuma, Yukarcin, Vegzelma). It is a direct competitor in mAb biosimilars across oncology and immunology, and like Polpharma pursues global out-licensing and direct commercialization in select geographies.
  • Samsung Bioepis: Samsung Bioepis is a major biosimilar developer commercializing multiple biosimilars (etanercept, adalimumab, trastuzumab, ranibizumab/SB11, bevacizumab). It directly competes with Polpharma's Ranivisio in the ranibizumab biosimilar market and pursues an out-licensing model with Biogen/Samsung.
  • Biocon Biologics: Biocon Biologics is a leading biosimilar developer (trastuzumab, bevacizumab, adalimumab, pegfilgrastim, insulin glargine) with integrated manufacturing. Like Polpharma, it uses out-licensing partners (Viatris) for global reach and is pursuing its own pipeline in autoimmune and oncology biosimilars.
  • Zydus Lifesciences: Zydus Lifesciences (Cadila) is a vertically integrated Indian biosimilar and generics developer that commercializes its own products in the US, India, and emerging markets. It is a Polpharma commercialization partner for NUFYMCO in the US and pursues a directly comparable biosimilar portfolio across immunology, oncology, and ophthalmology.
  • Alvotech: Alvotech is a vertically integrated biosimilar developer and manufacturer with a comparable focus on monoclonal antibody biosimilars (ranibizumab, adalimumab, ustekinumab, denosumab). Like Polpharma, it operates a hub-and-spoke model with manufacturing in Iceland/India and global commercialization partners, and competes directly in the ophthalmology biosimilar space with Polpharma's Ranivisio.
  • Formycon AG: Formycon is Polpharma's Bioeq AG joint venture partner and an independent biosimilar developer (FYB201 ranibizumab, FYB202/203 ustekinumab, FYB206 Keytruda biosimilar). It is a direct comparable in biosimilar pipeline strategy and has the same IP/commercialization partner model.

Broad incumbents

  • Amgen: Amgen operates a biosimilar business unit (Amgevita, Kanjinti, Mvasi, Soliris biosimilars) as part of a much broader biopharma portfolio. It is a relevant comparable given Polpharma's mAb biosimilar focus, though Amgen is also a competitor (e.g., Amgevita vs. adalimumab biosimilars) and a peer biologics developer.
  • Sandoz: Sandoz (recently spun off from Novartis) is the world's largest generic and biosimilar medicines company, developing and commercializing biosimilars (Hyrimoz, Omnitrope, Erelzi, Zessly, Tyruko). It is both Polpharma's largest commercial partner (Tyruko global rights) and a competitor in the biosimilar space.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a biosimilars business, including Tbo-filgrastim and partnerships (Polpharma's Ranivisio in EU/Canada). It is both a direct competitor in biosimilars and a Polpharma commercialization partner, making it a relevant broad-incumbent peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Polpharma Biologics social profiles

Digital presence

Polpharma Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polpharma Biologics leadership team

Management profile

Number of profiles

Profiles12 records

Polpharma Biologics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Polpharma Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polpharma Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polpharma Biologics

What does Polpharma Biologics do?

Polpharma Biologics develops and manufactures biosimilar medicines through integrated capabilities spanning cell line development, process development, clinical manufacturing, and commercial-scale production using mammalian and microbial expression systems. The company out-licenses its biosimilars (natalizumab Tyruko®, ranibizumab Ranivisio®/NUFYMCO®, plus pipeline candidates PB016, PB018, PB019) to global pharmaceutical partners who commercialize, market, and distribute them in licensed territories worldwide.

Is Polpharma Biologics a public or private company?

Polpharma Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Polpharma Biologics founded?

Polpharma Biologics was founded in 2019. It employs 251 to 500 people.

Where is Polpharma Biologics based?

Polpharma Biologics is headquartered in Zug, Switzerland, in the Europe region.

How does Polpharma Biologics make money?

Three revenue lines are on record. Biosimilar Out-licensing is the primary driver. The others are CDMO Services and joint Venture (Bioeq).

Who are Polpharma Biologics's main competitors?

Direct peers on record are Coherus BioSciences, Celltrion, Samsung Bioepis, Biocon Biologics, Zydus Lifesciences, Alvotech and Formycon AG. Broad incumbents are Amgen, Sandoz and Teva Pharmaceutical Industries.

Does Polpharma Biologics have an API?

No public API is recorded for Polpharma Biologics.

What industry is Polpharma Biologics in?

Polpharma Biologics's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAIAFAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Drug Store NewsFresenius receives FDA, EMA acceptance for review of vedolizumab biosimilar candidateFresenius Kabi's biosimilar candidate PB016 has received acceptance for review by the FDA and EMA. The applications, submitted by Polpharma Biologics S.A., concern a biosimilar to vedolizumab, used for treating ulcerative colitis and Crohn’s disease.PharmaTimesPolpharma Biologics gains FDA and EMA review acceptancesPolpharma Biologics announced FDA and EMA review acceptances for PB016, a vedolizumab biosimilar for ulcerative colitis and Crohn's disease. The biosimilar will be manufactured by Polpharma, with Fresenius Kabi holding exclusive global commercialization rights. The company cited the acceptances as a major milestone in its development programme.YahooPolpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar CandidatePolpharma Biologics International AG announced that the U.S. FDA and European EMA have accepted for review their regulatory applications for PB016, a proposed biosimilar candidate to Takeda's Entyvio (vedolizumab) for treating moderately to severely active ulcerative colitis and Crohn's disease. The biosimilar was developed and will be manufactured by Polpharma Biologics, while Fresenius Kabi holds exclusive global commercialization rights excluding the Middle East and North Africa. Regulatory approval of PB016 could expand patient access to affordable biologic therapies for inflammatory bowel disease, which affects approximately 2.4 million patients in the US and 2.5–3 million patients in Europe.FinancialContent Business PagePolpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar CandidatePolpharma Biologics International AG announced that the U.S. Food and Drug Administration and the European Medicines Agency have accepted for review its Biologics License Application and Marketing Authorisation Application for PB016, a proposed biosimilar to Takeda's Entyvio (vedolizumab) for treating ulcerative colitis and Crohn's disease. The biosimilar candidate was developed and will be manufactured by Polpharma Biologics, while Fresenius Kabi holds exclusive global commercialization rights excluding the Middle East and North Africa. The regulatory acceptances represent significant milestones validating Polpharma Biologics' biosimilar development program, with clinical trials having included a Phase 1 study in healthy volunteers and a Phase 3 study in ulcerative colitis patients.The Pharma LetterPolpharma Biologics’ Entyvio biosimilar accepted for FDA, EMA reviewPolpharma Biologics said the FDA and EMA accepted its regulatory filings for PB016, a biosimilar to Takeda's Entyvio. The applications cover an intravenous formulation for adults with moderately to severely active ulcerative colitis and Crohn's disease.BioSpaceFresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar CandidateFresenius Kabi announced that the U.S. FDA and EMA accepted for review the BLA and MAA for PB016, a proposed intravenous vedolizumab biosimilar. The company holds exclusive commercialization rights pending approval, targeting inflammatory bowel disease patients.MorningstarPolpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar CandidatePolpharma Biologics announced that the FDA and EMA accepted for review its BLA and MAA for PB016, a vedolizumab biosimilar to Entyvio for ulcerative colitis and Crohn's disease. The company will manufacture PB016, with Fresenius Kabi holding exclusive global commercialization rights pending approvals.Business Wire BlogPolpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar CandidatePolpharma Biologics International AG announced that the FDA and EMA have accepted for review its Biologics License Application and Marketing Authorisation Application for PB016, a proposed biosimilar to Takeda's Entyvio (vedolizumab) for treating adults with moderately to severely active ulcerative colitis and Crohn's disease. The biosimilar candidate was developed and will be manufactured by Polpharma Biologics, while Fresenius Kabi holds exclusive global commercialization rights excluding the Middle East and North Africa. The development program included Phase 1 and Phase 3 clinical trials demonstrating biosimilarity to the reference product.PharmExecPharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing AgreementChemomab Therapeutics and Scipher Medicine announced an all-stock merger to advance an anti-CCL24 antibody into an AI-guided Phase II rheumatoid arthritis trial. Separately, Teva entered a global licensing agreement with Polpharma Biologics for exclusive commercialization rights to a proposed ocrelizumab biosimilar across major markets. Both deals reflect ongoing consolidation and strategic positioning within the specialty pharma and biosimilars space.AInvestTeva Claims Top Turnover Spot Amid Record Volume Surge on Polpharma Biosimilar DealTeva Pharmaceutical Industries announced a global licensing agreement with Polpharma Biologics to commercialize a biosimilar candidate to Roche's blockbuster multiple sclerosis therapy Ocrevus, covering key markets including the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. On July 10, 2026, Teva shares fell 0.45% but recorded $220 million in daily turnover—a 30.42% increase from the previous day—propelling the company to the top spot in market turnover. The partnership, aligned with Teva's "Pivot to Growth" strategy, positions Teva to lead regulatory submissions and commercialization while Polpharma retains development and manufacturing responsibilities, with the deal targeting Roche's $7 billion Ocrevus franchise.